The latest news:

• Meta-analysis of cancer cell lines genomes based on their response to ttfields.         They found a link between some genes and the tumor's response to TTF. This may open the door to find out why it works so well on some people and not at all on others. Perhaps this may lead to a screening test to determine if it is worth even trying or better yet to adding a drug that will allow TTF to work for everyone. Exciting concept. 
  



• Overcoming cell size escape from tumor treating fields using a varying frequency treatment paradigm in vitro.         Fascinating article on how cells might become resistent to TTF and a simple way to fix that. (Simple in theory - but not yet available. I am sure they are working on it).
  



• Response assessment of novoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma.         An update on the trial for recurrent GBM. A little better result than originally reported last year. Still not good enough but it is the best of approved treatments. 
  



• Safety analysis of bevacizumab plus NovoTTF-100A in patients with Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas.         They found it is safe to mix Avastin and TTF but it did not do better than either alone. However, this was a very small study - only 6 patients had Avastin and TTF at the same time so it is hard to know how they would have done without any treatment. 
  



• Effect of tumor-treating fields on DNA repair in cancer cell lines.         This shows that adding TTF to radiation may result in a big increase in the effectiveness of the radiation. However, this was only in the test tube and on renal cell cancer and not brain cancer so more work needs to be done before we can say it is good to use with brain tumor radiation.
  



• Brain Tumor Awareness Day - Daily Living While Coping With A Brain Tumors         This is a free event presented by our friends at Mt Sinai.  Sounds good.